Abstract #4804

Evaluate the Feasibility of Delayed Contrast Extravasation MRI to Delineate Sub-volume Target in brain tumors Radiotherapy.

Yinxing Wang¹, Guanzhong Gong¹, Weiqiang Dou², Weiyin Vivian Liu², and Yong Yin¹

¹Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China, ²GE Healthcare, MR Research China, Beijing, China

Delayed contrast extravasation MRI (DCEM) could could differentiate regions of contrast agent clearance as an active tumor from regions of contrast agent accumulation as non-tumor tissues. By comparing the sub-volume of active tumor and non-tumor from DCEM with non-liquefaction necrosis and liquefaction from T2WI, our results showed that compared to liquefaction necrosis regions of the T2WI, the DCEM has advantages in distinguishing liquefaction area and could clearly differentiate sub-volume of active tumor from non-liquefaction. The application of DCEM was thus feasibly to guide the delineation of sub-volume target in brain tumor.

This abstract and the presentation materials are available to members only; a login is required.

Join Here